Boston Scientific (NYSE:BSX) Updates FY 2025 Earnings Guidance

Boston Scientific (NYSE:BSX) updated its FY 2025 earnings guidance on Wednesday. The company provided earnings per share guidance of 2.800-2.870 for the period, compared to the consensus earnings per share estimate of 2.810. The company issued revenue guidance of $18.8 billion-$19.2 billion, compared to the consensus revenue estimate of $18.8 billion. Boston Scientific also updated its Q1 2025 guidance to 0.660-0.680 EPS.

Analysts Set New Price Targets

A number of analysts have issued reports on BSX shares. Raymond James boosted their price objective on shares of Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a report on Thursday. TD Cowen boosted their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Canaccord Genuity Group upped their price target on shares of Boston Scientific from $98.00 to $101.00 and gave the stock a “buy” rating in a report on Monday, December 9th. JPMorgan Chase & Co. upped their price target on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “overweight” rating in a report on Monday, December 16th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Boston Scientific in a report on Thursday. One research analyst has rated the stock with a hold rating, twenty-two have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $104.26.

Boston Scientific Stock Up 0.0 %

NYSE BSX traded up $0.04 on Thursday, hitting $105.01. 6,241,721 shares of the company were exchanged, compared to its average volume of 6,229,090. The company has a market cap of $154.76 billion, a PE ratio of 86.78, a PEG ratio of 2.68 and a beta of 0.80. Boston Scientific has a 12 month low of $64.39 and a 12 month high of $107.17. The stock has a fifty day moving average of $94.30 and a 200-day moving average of $86.84. The company has a current ratio of 1.48, a quick ratio of 1.02 and a debt-to-equity ratio of 0.44.

Boston Scientific (NYSE:BSX) last released its quarterly earnings data on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a net margin of 11.26% and a return on equity of 17.23%. As a group, analysts forecast that Boston Scientific will post 2.46 earnings per share for the current year.

Insider Activity

In other news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the completion of the transaction, the executive vice president now owns 978 shares in the company, valued at $87,306.06. This trade represents a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Edward J. Ludwig sold 4,877 shares of Boston Scientific stock in a transaction dated Thursday, November 21st. The stock was sold at an average price of $91.63, for a total transaction of $446,879.51. Following the completion of the transaction, the director now owns 39,398 shares of the company’s stock, valued at $3,610,038.74. The trade was a 11.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 47,302 shares of company stock worth $4,464,725 over the last quarter. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.